Literature DB >> 10235615

Highly active antiretroviral therapy leading to resolution of porphyria cutanea tarda in a patient with AIDS and hepatitis C.

J D Rich1, E Mylonakis, R Nossa, R M Chapnick.   

Abstract

The association between HIV infection and porphyria cutanea tarda (PCT) is not well established. Since almost all HIV-infected patients with PCT previously described in the literature had additional risk factors for PCT, it is still unclear if HIV infection and not a cofactor such as hepatitis C virus is the trigger for PCT in this population. We describe a patient with AIDS and hepatitis C who developed bullous lesions due to PCT. The cutaneous lesions persisted for 18 months and resolved after he was placed on highly active antiretroviral therapy for HIV. No other therapeutic interventions were undertaken, while exposure to other known precipitants remained unchanged. During follow-up, skin lesions reappeared when the patient discontinued antiretroviral therapy, but PCT lesions again resolved after he restarted highly active antiretroviral therapy and HIV infection was controlled. This case supports the hypothesis that a direct causative relationship exists between HIV and the development of PCT.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10235615     DOI: 10.1023/a:1026681218915

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  13 in total

1.  Porphyria cutanea tarda and acquired immunodeficiency syndrome: pathogenetic implications.

Authors:  M T Herranz; A el Amrani; P Aranegui; J F Jiménez-Alonso; J M Ródenas; R M Vivaldi
Journal:  Arch Dermatol       Date:  1991-10

2.  Hepatitis C virus and human immunodeficiency virus infection can alter porphyrin metabolism and lead to porphyria cutanea tarda.

Authors:  A Blauvelt
Journal:  Arch Dermatol       Date:  1996-12

3.  Porphyria cutanea tarda as initial presentation of the acquired immunodeficiency syndrome in two patients.

Authors:  P Reynaud; K Goodfellow; F Svec
Journal:  J Infect Dis       Date:  1990-05       Impact factor: 5.226

4.  Abnormal urinary coproporphyrin levels in patients infected by hepatitis C virus with or without human immunodeficiency virus. A study of 177 patients.

Authors:  B Cribier; D Rey; G Uhl; C Le Coz; C Hirth; E Libbrecht; D Vetter; J M Lang; F Stoll-Keller; E Grosshans
Journal:  Arch Dermatol       Date:  1996-12

5.  Porphyria cutanea tarda remission.

Authors:  L B Siegel; B B Eber
Journal:  Ann Intern Med       Date:  1994-08-15       Impact factor: 25.391

6.  Porphyria cutanea tarda in association with human immunodeficiency virus infection: it is related to hepatitis C virus infection?

Authors:  J Castanet; J P Lacour; J Bodokh; S Bekri; J P Ortonne
Journal:  Arch Dermatol       Date:  1994-05

7.  Abnormal serum porphyrin levels in patients with the acquired immunodeficiency syndrome with or without hepatitis C virus infection.

Authors:  N Nomura; S Zolla-Pazner; M Simberkoff; M Kim; S Sassa; H W Lim
Journal:  Arch Dermatol       Date:  1996-08

Review 8.  Porphyria cutanea tarda.

Authors:  G H Elder
Journal:  Semin Liver Dis       Date:  1998       Impact factor: 6.115

9.  Porphyria cutanea tarda associated with the acquired immune deficiency syndrome.

Authors:  P S Wissel; P Sordillo; K E Anderson; S Sassa; R L Savillo; A Kappas
Journal:  Am J Hematol       Date:  1987-05       Impact factor: 10.047

Review 10.  Human immunodeficiency virus infection and porphyria cutanea tarda: coexistence of risk factors or causative association?

Authors:  F McAlister; K McClean; P G Hamilton; S Houston
Journal:  Clin Infect Dis       Date:  1995-02       Impact factor: 9.079

View more
  2 in total

1.  Human Immunodeficiency Virus Associated Sporadic Nonfamilial Porphyria Cutanea Tarda.

Authors:  Sibashish Kamal Guha; Debabrata Bandyopadhyay; Abanti Saha; Niharika Ranjan Lal
Journal:  Indian J Dermatol       Date:  2016 May-Jun       Impact factor: 1.494

2.  Porphyria cutanea tarda in a HIV- positive patient.

Authors:  Valéria Aparecida Zanela Franzon; Emanuella Stella Mikilita; Fernanda Henriques Camelo; Rosana Camargo
Journal:  An Bras Dermatol       Date:  2016 Jul-Aug       Impact factor: 1.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.